DataMeds AI (MEDS) Common Equity (2023 - 2026)

DataMeds AI (MEDS) has reported Common Equity for 4 consecutive years, with -$15.1 million the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 436.31% year-over-year to -$15.1 million; the trailing twelve-month figure through Mar 2026 stood at -$15.1 million (down 436.31% YoY), and the FY2025 full-year result was -$12.4 million, down 284.84% from the prior year.
• Common Equity fell to -$15.1 million in Q1 2026 per MEDS's latest filing, from -$12.4 million in the prior quarter.
• Across five years, Common Equity topped out at $10.0 million in Q3 2024 and bottomed at -$15.1 million in Q1 2026.
• Historically, Common Equity has averaged -$766054.5 across 4 years, with a median of -$997589.5 in 2023.
• The sharpest annual moves came in 2024 and 2026: Common Equity surged 332.19% in 2024, then plunged 436.31% in 2026.
• Over 4 years, Common Equity stood at -$2.9 million in 2023, then soared by 332.19% to $6.7 million in 2024, then plunged by 284.84% to -$12.4 million in 2025, then slipped by 21.0% to -$15.1 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered -$15.1 million, -$12.4 million, and $6.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.